QUOTE AND NEWS
StreetInsider.com  Mar 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/AcelRx+Pharma+%28ACRX%29+Names+Timothy+Morris+as+CFO/9312699.html for the full story.
SeekingAlpha  Mar 4  Comment 
AcelRx Pharmaceuticals, Inc. (ACRX) Q4 2013 Earnings Conference Call March 3, 2014 4:30 PM ET Executives James Welch – VP and CFO Richard King – President and CEO Analysts Louise Chen – Guggenheim Partners Randall...
StreetInsider.com  Mar 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/AcelRx+Pharmaceuticals+%28ACRX%29+Posts+Q4+Loss+of+18cShare/9238032.html for the full story.
SeekingAlpha  Feb 14  Comment 
By Scott Matusow: Written by Scott Matusow and Kyle Dennis. This week we want to highlight several biotechs with catalysts coming up in the near future. These price driving catalysts may include FDA approval decisions, FDA Advisory Committee...
StreetInsider.com  Dec 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AcelRx+Pharma+%28ACRX%29+Draws+%2415M+from+New+%2440M+Facility/8994254.html for the full story.
FierceBiotech  Dec 16  Comment 
The Redwood City, CA-based biotech is pocketing $30 million upfront from Germany's Gr ü nenthal, which will also pay up to $220 million more in milestones for the treatment, nabbing European and Australian marketing rights.
Benzinga  Dec 16  Comment 
AcelRx Pharmaceuticals (Nasdaq: ACRX) and Grunenthal GmbH announced today that they have entered into a commercial collaboration, covering the territory of the European Union, certain other European countries and Australia for ZALVISO™...
Benzinga  Dec 13  Comment 
Performance Technologies (NASDAQ: PTIX) surged 25.84% to $3.75 in the pre-market session after the company agreed to be acquired by Sonus Networks NASDAQ: SONS) for $3.75 per share in cash. Sonus Networks (NASDAQ: SONS) soared 12.54% to $3.14...
StreetInsider.com  Dec 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AcelRx+Pharma+%28ACRX%29+Presents+Statistically+Significant+Interim+ARX-04+Phase+2+Data/8976383.html for the full story.
StreetInsider.com  Dec 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/AcelRx+Pharma+%28ACRX%29+Adds+Covenant+Health+CEO+Afable+to+Board/8967804.html for the full story.




 
TOP CONTRIBUTORS

AcelRx (NASDAQ:ACRX) is a pharmaceutical company which develops and sells treatments for acute and breakthrough pain. In particular, the product would help with post-operative pain. AcelRx has completed Phase 2 and is preparing to conduct two Phase 3 clinical trials for its lead product.[1]

Acute and breakthrough pain associated with the post-operation period is often treated with intravenous (IV) opioid injections. These tend to have negative side effects due to the usage of morphine. In addition, there can be delivery and programming errors from the complex infusion pumps used to provide the patients with the opioid. AcelRx's lead candidate involves a patient administered dosage sublingual, or below the tongue. AcelRx also uses Sufentanil rather than morphine.[2]

The company's initial public offering of stock on the NASDAQ occurred on February 10, 2011. The company offered 8M shares each for $5. The company originally planned to sell 5.8M shares within the range of $12-$14. This would have made the deal worth $75.4M, but the drop in price brought the total deal to $40M even after the rise in shares sold. The lead underwriter of the deal was Piper Jaffray Companies (PJC). Canaccord Capital (BER:C6U), Cowen Group (COWN), and JMP Group (JMP) acted as comanagers.[3]

Because AcelRx does not have a commercially viable yet, the company is still in the pre-revenue stage. As a result, the company has incurred high Research & Development expenses without making money. For the first 9 months of 2010, AcelRx's net loss was $10.8M, 58% of which was from research and development expenses. [4]

References

  1. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg1
  2. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Sufentanil NanoTabs" pg1-2
  3. Renaissance Capital - IPO Home "AcelRx prices IPO at $5, below the original $12-$14 range" 11 Feb 2011
  4. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Summary Financial Data" pg10
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki